Alzamend Neuro, Inc. ALZN
Alzamend Neuro, Inc. (Nasdaq: ALZN) is a CNS/neurology/psychiatry drug developer. Its lead program, AL001, is in Phase 2 for Bipolar disorder (also Alzheimer's, MDD, PTSD). Its next catalyst on record is AL001: Topline data, Phase II BD 'Lithium in Brain' study (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AL001 — Topline data, Phase II BD 'Lithium in Brain' study (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AL001 | Bipolar disorder (Phase II 'Lithium in Brain' study) | small molecule | Phase 2 |
| AL001 | MDD, PTSD | small molecule | Phase 2 |
| AL001 | Alzheimer's disease | small molecule | Phase 2 |
| ALZN002 | Mild to moderate Alzheimer's dementia | cell therapy | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.